Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Equity (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 15 years of Return on Equity data on record, last reported at 0.38% in Q4 2025.

  • For Q4 2025, Return on Equity fell 12.0% year-over-year to 0.38%; the TTM value through Dec 2025 reached 0.38%, down 12.0%, while the annual FY2025 figure was 1.03%, 77.0% down from the prior year.
  • Return on Equity reached 0.38% in Q4 2025 per LCTX's latest filing, up from 0.93% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.13% in Q2 2021 and bottomed at 0.93% in Q3 2025.
  • Average Return on Equity over 5 years is 0.35%, with a median of 0.36% recorded in 2024.
  • Peak YoY movement for Return on Equity: skyrocketed 33bps in 2021, then tumbled -62bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.13% in 2021, then plummeted by -219bps to 0.43% in 2022, then rose by 22bps to 0.33% in 2023, then rose by 22bps to 0.26% in 2024, then plummeted by -46bps to 0.38% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.38% in Q4 2025, 0.93% in Q3 2025, and 0.51% in Q2 2025.